681 results about "Cisplatin" patented technology

The present invention relates to a pentacyclic triterpanoid derivative of multiple-oxide substitution of the A ring and the C ring and the medicine salt or solvate of the derivative, and the present invention also relates to the preparation method, the drug combination, and medical use of the derivative. The compound of the present invention has the functions of inhibiting the activity of six human tumor cell strains in vitro, such as human prostate cancer cell (PC-3), nasopharyngeal carcinoma cells (CNE), oral squamous carcinoma cell(KB), human lung cancer cell (A549), human hepatoma cell (BEL-7404), and human cervix cancer cell (Hela), and the function of the invention is at the same magnitude of the positive control of cisplatin, thereby the compound can be used as expected antitumor drug. The compound of the present invention also inhibits the alpha glucosidase strongly, and the inhibiting effect is greater than the positive control of acarbose, thereby the compound can be used as expected medicine for preventing and treating diabetes and the treatment of the virus diseases.

The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to said patient simultaneously or sequentially a therapeutically effective amount of a combination of an anti-cancer agent or treatment that elevates pAkt levels in tumor cells and an IGF-1R kinase inhibitor of Formula (I) (e.g. OSI-906). Examples of such anti-cancer agents or treatments include doxorubicin, cisplatin, and ionizing radiation. The present invention also provides a pharmaceutical composition comprising an anti-cancer agent that elevates pAkt levels in tumor cells and an IGF-1R kinase inhibitor of Formula (I), in a pharmaceutically acceptable carrier. The present invention also provides a method of identifying tumor cells that will respond most favorably to treatment with a combination of an anti-cancer agent or treatment that elevates pAkt levels in tumor cells and an IGF-1R kinase inhibitor.

The invention discloses a beta-carboline ruthenium compound. The molecular formula of the beta-carboline ruthenium compound is [Ru (N^N) 2 (Nh) XClY] (A^A)z, wherein N^N is selected from bpy or phen; A^A is selected from PF6 or SO3CF3; X is equal to 1 or 2, Y is equal to 2-X, and Z is equal to 1 or 2; or the molecular formula of the beta-carboline ruthenium compound is [Ru (N^N) 2 (1-Py-betaC)] (PF^)2, wherein N^N is selected from bpy, phen or DIP. On a molecular mechanism, the invention proves that the beta-carboline ruthenium compound can be used for treating cancers and has a better effectthan the effects of that of the traditional metal compound cisplatin with wide application and ruthenium compounds NAMI-A in clinical tests; . Thethe beta-carboline ruthenium compound for treating the cancers as an autophagic cell inducer fills the blank of the prior art and develops a new line for developing a new generation of high-efficiency medicaments for treating malignant tumors.

The invention provides a water-soluble fullerene derivative, composite and the applications in the preparation process of medicament used for inhibiting growth and transfer of tumor; the derivative is fullerols presented by a general formula: C60OxHy; wherein, y is more than 10 and less than or equal to x; x is less than 50 and more than or equal to y; alternatively, the derivative is fullerene carboxyl derivative presented by the general formula C60(C(COOH)2)n; wherein, n is equal to 1-3; the tumor inhibiting composite comprises the grains of the water-soluble fullerene derivative and pharmaceutically acceptable carrier. The invention has the advantages that: compared with cyclophosphamide, cisplatin, paclitaxel, and the like, which are generally applied to clinic at present; the fullerols and carboxylic fullerene nano grains have small dosage, low toxicity and can inhibite the growth and transfer of the tumor.

The invention relates to an application of antagonizing and/or blocking IL-6/IL-6R/gp130 signaling pathway in treatment of anti-hepatoma, and specifically relates to an application of an antagonist and/or a blocking agent of the IL-6/IL-6R/gp130 signaling pathway and conventional liver cancer treatment drugs (such as cisplatin, doxorubicin and sorafenib) in preparation of anti-hepatoma drug compositions. The composition provided by the invention has significant curative effect for the liver cancers and has the advantages of small toxic and side effects, capability for synergizing with the conventional liver cancer treatment drugs and increasing the effect of the conventional anti-hepatoma treatment, and the like.

Described herein are platinum-based brush-arm star polymers (Pt-BASPs), or a pharmaceutical composition thereof, for delivery of platinum-based agents, such as cisplatin. Also provided are methods and kits involving the Pt-BASPs, or a pharmaceutical composition thereof, for treating proliferative diseases such as cancers (e.g., lung cancer, head-and-neck cancer, esophagus cancer, stomach cancer, breast cancer, pancreas cancer, liver cancer, kidney cancer, or prostate cancer) in a subject.

Provided is a complex comprising cisplatin encapsulated therein in a form in which a chlorine ion thereof is ligand-exchanged with a carboxyl anion of a block copolymer comprising poly(ethylene glycol)-poly(glutamic acid). This complex can be a medicinal preparation to which a novel dosage form decreased in toxicity can be applied.

Compositions containing epidithiodioxopiprazines and methods of their use are provided. Epidithiodioxopiprazines can be isolated from natural resources or synthesized de novo. Moreover, epidithiodioxopiprazines, including Verticillin A, are shown to effectively sensitize multiple types of tumor cells to TRAIL-induced apoptosis. In addition, epidithiodioxopiprazines, including Verticillin A, are shown to effectively overcome cancer cell resistance to existing drugs (i.e. Etoposide, Cisplatin, 5-FU and Doxorubicin). Therefore, compositions and methods are provided for use in sensitizing target cancer cells to death receptor- and other anticancer drugs-induced apoptosis. Methods of treating cancer in a subject in need thereof are also provided.

Acridine containing cisplatin compounds have been disclosed that show greater efficacy against cancer than other cisplatin compounds. Methods of delivery of those more effective cisplatin compounds to the nucleus in cancer cells is disclosed using one or more amino acids, one or more sugars, one or more polymeric ethers, C_1-6alkylene-phenyl-NH—C(O)—R₁₅, folic acid, α_vβ₃ integrin RGD binding peptide, tamoxifen, endoxifen, epidermal growth factor receptor, antibody conjugates, kinase inhibitors, diazoles, triazoles, oxazoles, erlotinib, and/or mixtures thereof; wherein R₁₅ is a peptide.

The present invention relates to the application of curcumin in preparing medicine for inverting drug resistance of malignant tumor. The malignant tumor includes oophoroma, cervix cancer, endometrial carcinoma, lung cancer, liver cancer, etc. The effective component of the medicine includes curcumin, demethoxy curcumin, didemethoxy curcumin or their mixture. The medicine consists of the effective component, solvent, stabilizer and co-solvent. It is used to act on drug resisting cell of malignant tumor alone or together with cisplatin or other chemotherapeutic medicine. Compared with traditional drug resistance inverting medicine preparation, the present invention has the advantages of small dosage, high safety and high efficiency.

A method for encapsulating cisplatin and other positively-charged drugs into liposomes having a different lipid composition between their inner and outer membrane bilayers is disclosed. The liposomes are able to reach primary tumors and their metastases after intravenous injection to animals and humans. The encapsulated cisplatin has a high therapeutic efficacy in eradicating a variety of solid human tumors including but not limited to breast carcinoma and prostate carcinoma. Combination of the encapsulated cisplatin with encapsulated doxorubicin or with other antineoplastic drugs are claimed to be of therapeutic value. Also of therapeutic value in cancer eradication are claimed to be combinations of encapsulated cisplatin with a number of anticancer genes including but not limited to p53, IL-2, IL-12, angiostatin, and oncostatin encapsulated into liposomes as well as combinations of encapsulated cisplatin with HSV-tk plus encapsulated ganciclovir.

Provided is a method for treating a patient having lung cancer. The method includes administering a lipid composition containing cisplatin to the patient's respiratory tract over the course of at least 2 treatment cycles. At least about 15 mg/m² of cisplatin is administered in each treatment cycle, and there is no more than 2 weeks between treatment cycles.

The present invention relates to a method of treating cancer in a subject in need thereof, by administering to the subject a combination of sodium meta arsenite and/or arsenic trioxide and a cytotoxic anticancer agent, such as cisplatin, adriamycin, and taxane, such as larotaxel, orataxel, tesetaxel, docetaxel or paclitaxel. The arsenic compound(s) and cytotoxic anti-cancer agent may be administered together in a composition or separately as a combination therapy.

The invention relates to a cisplatin precursor medicine, of which a structural formula is c,c,t-[Pt(NH3)2Cl2(O2CCH2CH2CH2CH2CH3)2]. The cisplatin precursor medicine molecule contains a -O2CCH2CH2CH2CH2CH3 group which has stronger hydrophobicity and better stability, and is easy to pack to be prepared into a nanometer dosage form of high drug load. Meanwhile, the -O2CCH2CH2CH2CH2CH3 group is easily reduced into cisplatin in an organism to act to cancer cells. In addition, the invention also relates to a preparation method of the cisplatin precursor medicine, and a core-shell nano-particle containing the same as well as a preparation method thereof.

The use of the maximum tolerated dose (MTD) of individual drugs to determine appropriate administration ratios of drugs for combination therapy, wherein the ratios of drugs are fixed based on the same percentage of the MTD for each drug. Furthermore, antineoplastic compositions comprising liposomal encapsulated gemcitabine alone or in combination with free or liposomal encapsulated antineoplastic agents, such as idarubicin, irinotecan, etopside, cisplatin, cyclophosphamide, doxorubicin, or vincristine are diclosed.

A recombinant adenovirus configurator deleted EIA coding sequence in human adenovirus type 5 genom and its application to diagnosing and treating tumor are disclosed. The site-directed mutation, PCR augmentation, enzyme severing, linking, subcloning, transfection, and single-cloning purification of recombinant adenovirus technologies, and the deleted EIA (382-1630 nt) sequence are used to screen the recombinant adenovirus configurator of being unable to express the EIA function protein. It can specifically kill tumor cells, but not normal cells, and has synergestic action to chemicotherapeutic medicines.

The invention provides a medicament for treating digestive tract side effects caused by cancer chemotherapy, comprising the following medical materials: 700-800g of astragalus, 250-300g of dwarf lilyturf root, 200-250g of red ginseng, 200-250g of atractylodes, 200-250g of poria cocos, 200-250g of liquorice, 200-250g of figwort, 250-350g of dark plum, 200-250g of zedoary turmeric, 200-250g of angelica sinensis, 200-250g of ageratum, 200-250g of tangerine peel, and 250-350g of prepared pinellia tuber. The medicament for treating digestive tract side effects caused by cancer chemotherap obviously relieves vomiting response caused by copper sulfate and cisplatin, reduces the time of vomiting, delays vomiting generation, has remarkable function of reducing animal toxic side effects caused by anticancer drugs, and can improve the body immunity.

Kidney toxicity which is induced by cisplatin and other therapeutic and diagnostic agents, limits the effectiveness of the therapy or diagnosis. Modulation or depletion of T cells ameliorates the toxicity, permitting the use of cisplatin at levels and for durations which treat cancers more effectively. Modulation and depletion can be accomplished using antibodies for T cell surface antigens as well as using other molecules which effectively antagonize or down-regulate the cytokines and/or chemokines which T cells elaborate.

The invention concerns agonist anti-trkC antibodies, polypeptides, and polynucleotides encoding the same. The invention further concerns use of such antibodies, polypeptides and/or polynucleotides in the treatment and/or prevention of neuropathies, such as sensory neuropathies, including taxol-induced sensory neuropathy, cisplatin-induced sensory neuropathy, and pyridoxine-induced sensory neuropathy.